The estimated Net Worth of Shlomo Yanai is at least $19.6 Million dollars as of 10 May 2024. Mr. Yanai owns over 76,453 units of W.R. Grace & Co stock worth over $17,198,433 and over the last 12 years he sold GRA stock worth over $2,147,760. In addition, he makes $210,007 as Independent Director at W.R. Grace & Co.
Shlomo has made over 7 trades of the W.R. Grace & Co stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 76,453 units of GRA stock worth $5,350,945 on 10 May 2024.
The largest trade he's ever made was exercising 80,128 units of W.R. Grace & Co stock on 9 May 2023 worth over $5,608,159. On average, Shlomo trades about 8,559 units every 89 days since 2012. As of 10 May 2024 he still owns at least 245,727 units of W.R. Grace & Co stock.
You can see the complete history of Mr. Yanai stock trades at the bottom of the page.
Shlomo Yanai serves as Independent Director of the Company. Mr. Yanai is a senior advisor to Moelis & Company (since 2016). He served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until mid-2012, leading a period of significant growth in revenue and profitability. As Teva CEO, Mr. Yanai was ranked 20th in Fortune's Top CEO List in 2010. From 2012 to 2015, he served as an advisor to the Teva CEO and Board. Prior to Teva, he served four years as the Chief Executive Officer and President of ADAMA Agricultural Solutions Ltd. During his nearly 15 years as a corporate executive, Mr. Yanai successfully completed over 20 acquisitions. Prior to his business executive roles, he served for 32 years with the Israeli Defense Forces in a variety of leadership roles including head of the Israeli Security Delegation to the peace talks at Camp David, Shepherdstown and Wye River. He was Head of the Planning Branch of GHQ from 1998 to 2001 when he retired as a Major General. Mr. Yanai is a director of Amneal Pharmaceuticals, Inc. and PDL BioPharma, Inc. He previously served on the Boards of Cambrex Corporation, Protalix Biotherapeutics, Inc., Lumenis Ltd., Perrigo Company plc, and Sagent Pharmaceuticals, Inc. Mr. Yanai brings global industry leadership, specialty chemicals and pharmaceutical experience, and the perspective of a former Chief Executive Officer to the Grace Board
As the Independent Director of W.R. Grace & Co, the total compensation of Shlomo Yanai at W.R. Grace & Co is $210,007. There are 9 executives at W.R. Grace & Co getting paid more, with Andrew La Force having the highest compensation of $5,530,020.
Shlomo Yanai is 67, he's been the Independent Director of W.R. Grace & Co since 2018. There are 3 older and 7 younger executives at W.R. Grace & Co. The oldest executive at W.R. Grace & Co. is Christopher Steffen, 77, who is the Non-Executive Chairman of the Board.
Shlomo's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.
Over the last 21 years, insiders at W.R. Grace & Co have traded over $4,984,906 worth of W.R. Grace & Co stock and bought 3,232,783 units worth $199,186,832 . The most active insiders traders include R. Ted Weschler,, North Latitude Fund Lp40 No..., and Jeffry N Quinn. On average, W.R. Grace & Co executives and independent directors trade stock every 31 days with the average trade being worth of $3,732,707. The most recent stock trade was executed by William C. Dockman on 7 May 2021, trading 2,958 units of GRA stock currently worth $207,030.
Built on talent, technology, and trust, Grace is a leading global specialty chemical company. The company's two industry-leading business segments-Catalysts Technologies and Materials Technologies-provide innovative products, technologies, and services that enhance the products and processes of its customers around the world. With approximately 4,000 employees, Grace operates and/or sells to customers in over 60 countries.
W.R. Grace & Co executives and other stock owners filed with the SEC include: